TinkCells delivers physiologically-relevant liver tissue models through precision bioprinting and AI-driven perfusion culture. Accelerating "Drug Development" with platforms that predict human response.
From precision bioprinting to AI-controlled perfusion culture, our integrated platform delivers unmatched organoid fidelity and longevity.
Six-tool automatic exchange system with kinematic coupling precision. Prints vascularized liver organoids with sub-20 micron capillary resolution using our proprietary nano-support bath technology.
Revolutionary yield-stress fluid enabling freeform bioprinting of soft materials. Our nano-scale support bath recovers in <1 second, allowing complex vascular architectures impossible with traditional methods.
AI-controlled bioreactor maintaining physiological homeostasis for 30+ days. Five independent PID loops monitor temperature, pH, dissolved oxygen, glucose, and perfusion flow in real-time.
Our Technology-as-a-Service model delivers validated liver organoids on demand, with comprehensive metabolic and toxicity analysis.
Custom organoid architectures tailored to your assay needs. Upload CAD models or use our template library for standard liver tissue configurations.
Set-and-forget bioreactor operation with AI-driven metabolic monitoring. Real-time viability prediction with 82% accuracy using LSTM models.
Track OCR, GCR, albumin secretion, urea synthesis, and CYP450 activity. Export data to your LIMS or analysis pipeline via REST API.
Monitor all bioreactors remotely with real-time sensor data, alerts, and predictive fault detection. SQLite + S3 cloud sync for indefinite data retention.
Predict DILI risk earlier in development with physiologically-relevant models. Our organoids capture CYP450 metabolic profiles and show dose-dependent toxicity responses matching clinical data.
Study lipid accumulation, inflammation, and fibrosis in a controlled 3D environment. Long-term culture enables chronic disease progression studies impossible with 2D hepatocytes.
Patient-derived iPSC organoids for precision oncology and rare disease research. Test therapeutic hypotheses on genetically-matched tissue before clinical intervention.
Model hepatotropic virus infections (HBV, HCV, SARS-CoV-2) in a physiological hepatic microenvironment. Screen antiviral compounds with relevant metabolic context.
Join leading pharma and biotech companies using Tink Cells organoids to reduce preclinical attrition and predict human response.
Schedule a Consultation